This session is provided by American Association for the Study of Liver Diseases in collaboration with the Society for Immunotherapy of Cancer. Taking place at The Liver Meeting in San Diego, CA.
Multidisciplinary care is essential for the optimal management of patients with liver cancer. Hepatologists play a central role in liver cancer care by assessing and managing underlying liver disease. Skills unique to hepatology include stratifying severity of liver disease, identifying and managing portal hypertension, understanding liver metabolism, and managing liver related toxicity of immune and other oncologic therapies.
The overall goal of this program is to introduce and discuss novel paradigms of HCC management and the integration of hepatology into the systemic therapy of HCC. In the first session, we will explore European and Asian models of care delivery, assess the current state of systemic therapies, consider real-world application of clinical trials data to complex cases, and understand how to anticipate and manage side effects of systemic therapy.
Workforce demands in hepatology and oncology provide opportunities for cross discipline innovations in discovery and care delivery. In session 2 we will explore the regulatory, logistical, and infrastructural needs of systemic therapy delivery and models of combined specialty training. As the landscape of therapies evolves for liver cancer, we will consider the future of systemic therapy and how the AASLD can promote innovation in the field.
Part 1: Monday, November 18, 8 - 9:30 a.m. PT
Chairs:
- Neehar Parikh, MD, MS, FAASLD - University of Michigan Medical Center
- Tim Greten, MD - National Cancer Institute
Part 2: Monday, November 18, 11 a.m. - 12:30 p.m. PT
Chairs:
- Tamar Taddei, MD - Yale School of Medicine
- Mark Yarchoan, MD - Johns Hopkins University